乙型肝炎患者血清免疫球蛋白和补体C3/C4检测的意义*

doi:10.3969/j.issn.1672-5069.2015.02.018

Abstract

Lin Mengxin, Su Zhijun, Guo Ruyi. Detection of serum immune globulin and complement C3/C4?in patients with chronic hepatitis B and HBV-related liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 182-183.

References

[1] Jaroszewicz J,Serrano BC,Wursthorn K,et al. Hepatitis B surface antigen（HBsAg） levels in the natural history of hepatitis B virus（HBV）-infection:a European perspective. J Hepatol,2010,52:514-522.
[2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[3] Karino Y,Toyota J,Kumada H,et a1. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepaml Int,2010,4（1）：414-422.
[4] Walport MJ. Complement:First of two parts. New Engl J Med,2001,344:1058-1066.
[5] Lai CL,Shouval D,Lok AS,et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med,2006,354（10）:1011-1020.
[6] Inoue H,Mashimo Y,Funamizu M,et al. Association study of the C3 gene with adult and childhood asthma. J human genetics,2007,53:728-738.
[7] Wu YL,Yu CY. Molecular basis of complete complement C4 deficiency in two North-African families with systemic lupus erythematosus. Genes Immun,2009,10:433-445.
[8] Hunnangkul S,Nitsch D,Rhodes B,et al. Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus. Arth Rheuma,2008,58:1116-1124.
[9] Ishikawa T. Clinical features of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol,2010,16（20）：2463-2467.
[10] Brockman MA,Knipe DM.Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.Vaccine,2008,26（ Suppl 8）:194-199.
[11] Tan AT,Koh S,Gob W,e1 al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronjc hepatitis B. J Hepatol,2010,52：330-339.
[12] Zipfel PF,Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol,2009,9（10）：729-740.
[13] Engstrom G,Hedblad B,Janzon L,et a1. Complement C3 and CA in plasma and ineidence of myocardialinfarction and stroke:a population-based cohol study. Eur J Cardiovasc Prey Rehabil,2007,14（3）:392-397.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

Detection of serum immune globulin and complement C3/C4?in patients with chronic hepatitis B and HBV-related liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments